<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895894</url>
  </required_header>
  <id_info>
    <org_study_id>MMF2013</org_study_id>
    <nct_id>NCT01895894</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome</brief_title>
  <official_title>A Prospective, Randomized, Open-label Study Evaluating the Efficacy of Mycophenolate Mofetil in the Prevention of Relapse of Steroid Dependent Nephrotic Syndrome in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic nephrotic syndrome is generally responsive to steroid therapy, but some patients
      need other immunosuppressants to reduce steroid dependency. The long-term use should be
      restricted due to adverse effects of cyclosporine, such as hypertension and nephrotoxicity.

      Mycophenolate mofetil for steroid-dependent nephrotic syndrome has been reported to have
      similar efficacy and fewer undesirable effects to other drugs in mainly observational
      studies. To determine the efficacy of mycophenolate mofetil in the management of
      steroid-dependent nephrotic syndrome, the investigators designed this prospective randomized
      controlled study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>relapse free time</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>remission maintenance rate at 3, 6, 9, 12 months</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil 25~33mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <other_name>Myrept capsule/tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Steroid-dependent patients who had been on calcineurin inhibitors continuously for
             more than 1 year

          -  in complete remission

        Exclusion Criteria:

          -  Hereditary or secondary nephrotic syndrome

          -  Estimated glomerular filtration rate (GFR) &lt; 60 mg/min/1.73 m^2

          -  Body weight &lt;16 kg

          -  leukocytopenia (absolute neutrophil count &lt; 2000/mm^3) or anemia(Hct &lt; 25%)

          -  Severe gastrointestinal disease

          -  chronic or acute active infection (e.g. hepatitis B,C, herpes, varicella zoster)

          -  prior live vaccine inoculation within 6 weeks (from the study enrollment)

          -  GOT/GPT elevation or hyperbilirubinemia

          -  malignant disease

          -  Pregnant or Breast feeding

          -  Previous history of mycophenolate mofetil use

          -  Participation to other therapeutic trial within recent 3 months

          -  Deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Gyung Aurea Kang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Jin Choi</last_name>
    <phone>+82-2-2072-3584</phone>
    <email>ian0691@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-740</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 18, 2014</lastchanged_date>
  <firstreceived_date>July 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Gyung Kang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Nephrosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
